| Literature DB >> 28667373 |
Rotem Haviv1, Eden Oz1, Hermona Soreq2.
Abstract
MicroRNAs (miRNAs) are small non-coding RNA chains that can each interact with the 3'-untranslated region of multiple target transcripts in various organisms, humans included. MiRNAs tune entire biological pathways, spanning stress reactions, by regulating the stability and/or translation of their targets. MiRNA genes are often subject to co-evolutionary changes together with their target transcripts, which may be reflected by differences between paralog mouse and primate miRNA/mRNA pairs. However, whether such evolution occurred in stress-related miRNAs remained largely unknown. Here, we report that the stress-induced evolutionarily conserved miR-132-3p, its target transcripts and its regulated pathways provide an intriguing example to exceptionally robust conservation. Mice and human miR-132-3p share six experimentally validated targets and 18 predicted targets with a common miRNA response element. Enrichment analysis and mining in-house and web-available experimental data identified co-regulation by miR-132 in mice and humans of stress-related, inflammatory, metabolic, and neuronal growth pathways. Our findings demonstrate pan-mammalian preservation of miR-132's neuronal roles, and call for further exploring the corresponding stress-related implications.Entities:
Keywords: Cholinergic system; Pathway analysis; Stress; miRNA; miRNA-132
Mesh:
Substances:
Year: 2017 PMID: 28667373 PMCID: PMC5775983 DOI: 10.1007/s10571-017-0515-z
Source DB: PubMed Journal: Cell Mol Neurobiol ISSN: 0272-4340 Impact factor: 5.046
Fig. 1MiR-132 genomic location and structure. a Human miR-132′s genomic location, conservation, and promoter-related H3K4Me3 histone modification, adapted from the UCSC genome browser. b Stem-loop sequence of miR-132 in different organisms. miR-132 3p and 5p are indicated in bold. c, d Sequence and predicted stem-loop structure of human (c) and mouse (d) pre-miR-132. The mature miRNA sequences are indicated in blue for the 5′, and purple for the 3′. This figure was designed using the Vienna RNAfold webserver based on minimum free energy prediction (Color figure online)
Fig. 2Validated and predicted miR-132-3p targets in mice and humans. a Venn diagram of validated miR-132-3p targets in mice and humans. Targets containing validated or predicted conserved MREs are marked in dark blue and dark red, respectively. Targets without miR-132-3p MRE are marked in black. Kdm5a contains only 6/7 nucleotides of the predicted MRE and therefore is marked with (delta). b Venn diagram of validated and predicted targets of miR-132-3p in human (not to scale). Predicted transcripts were retrieved from Diana microT-CDS using a default threshold of 0.7 (Color figure online)
Human miR-132-3p validated targets and the references for their validation
| Gene name | References |
|---|---|
| TJAP1 | (Cambronne et al. |
| CRK | (Cambronne et al. |
| TLN2 | (Formosa et al. |
| RFX4 | (Cheng et al. |
| RB1 | (Park et al. |
| SOX5 | (Renjie and Haiqian |
| ZEB2 | (You et al. |
| CDKN1A | (Wu et al. |
| SIRT1 | (Strum et al. |
| IRAK4 | (Nahid et al. |
| FoxO1 | (Li et al. |
| STAT4 | (Huang et al. |
| SOX4 | (Li et al. |
| NR4A2 | (Yang et al. |
| AChE | (Hanin et al. |
| EP300 | (Lagos et al. |
| RASA1 | (Anand et al. |
| HBEGF | (Formosa et al. |
| MECP2 | (Han et al. |
Murine miR-132-3p validated targets and the references for their validation
| Gene name | References |
|---|---|
| FoxO3 | (Wong et al. |
| Pten | (Wong et al. |
| Paip2 | (Alvarez-Saavedra et al. |
| Lrrfip1 | (Choe et al. |
| Btg2 | (Alvarez-Saavedra et al. |
| Cacnb2 | (Carrillo et al. |
| Ptbp2 | (Smith et al. |
| P250GAP | (Vo et al. |
| Kdm5a | (Alvarez-Saavedra et al. |
| Mmp9 | (Jasińska et al. |
| Cyp2e1 | (Shukla et al. |
| NR4A2 | (Yang et al. |
| AChE | (Shaked et al. |
| EP300 | (Alvarez-Saavedra et al. |
| RASA1 | (Anand et al. |
| HBEGF | (Molnár et al. |
| MECP2 | (Alvarez-Saavedra et al. |
Fig. 3Human MECP2 3′-UTR The MREs for miR-483-5p (green) and miR-132-3p (red) and their locations in the 3′-UTR of MECP2 are marked (Color figure online)
Fig. 4Human miR-132 interaction network. A schematic representation of the interactions between miR-132-3p (pink), its validated (yellow), or putative (green) target genes and the proteins they interact with (blue). Interactions between the targets and putative targets themselves are indicated with dashed-lines (Color figure online)
Selected pathways predicted to be affected by miR-132-3p in Human
| Pathway | Number of genes | % of involved genes | FDR |
|---|---|---|---|
| Nervous system | |||
| Neurotrophin signaling pathway | 32 | 12.96 | 7.7E−19 |
| Cholinergic synapse | 17 | 6.88 | 9.6E−05 |
| Immune system | |||
| T cell receptor signaling pathway | 26 | 10.53 | 4.8E−14 |
| Chemokine signaling pathway | 31 | 12.55 | 5.2E−12 |
| B cell receptor signaling pathway | 18 | 7.29 | 5.4E−09 |
| Leukocyte transendothelial migration | 19 | 7.69 | 5.6E−06 |
| Natural killer cell-mediated cytotoxicity | 17 | 6.88 | 3.7E−04 |
| Metabolism | |||
| Inflammatory bowel disease (IBD) | 11 | 4.45 | 1.4E−02 |
| Insulin signaling pathway | 24 | 9.72 | 5.3E−09 |
| Insulin resistance | 18 | 7.29 | 9.5E−06 |
| Type II diabetes mellitus | 12 | 4.86 | 8.5E−05 |
| Cell cycle | |||
| Cell cycle | 38 | 15.38 | 1.7E−25 |
| Apoptosis | 18 | 7.29 | 8.0E−10 |
Pathways with more than 4% involved genes are listed. For each selected pathway, the numbers (out of 247 genes), percentage of involved genes, and FDR are shown
Selected common and unique enriched pathways in human and mice
| Pathway | FDR human | FDR mouse |
|---|---|---|
| Cell cycle | 1.7E−25 | 2.0E−19 |
| Neurotrophin signaling pathway | 7.7E−19 | 6.1E−11 |
| T cell receptor signaling pathway | 4.8E−14 | 1.5E−12 |
| Chemokine signaling pathway | 5.2E−12 | 1.9E−11 |
| Apoptosis | 8.0E−10 | 4.0E−06 |
| Insulin signaling pathway | 5.3E−09 | 2.5E−05 |
| B cell receptor signaling pathway | 5.4E−09 | 1.7E−15 |
| Leukocyte transendothelial migration | 5.6E−06 | 4.9E−12 |
| Insulin resistance | 9.5E−06 | 4.6E−07 |
| Type II diabetes mellitus | 8.5E−05 | 4.7E−06 |
| Cholinergic synapse | 9.6E−05 | 1.0E−08 |
| Non-alcoholic fatty liver disease (NAFLD) | 2.8E−04 | 1.7E−02 |
| Natural killer cell-mediated cytotoxicity | 3.7E−04 | 2.1E−07 |
| Shigellosis | 1.4E−02 | – |
| Epithelial cell signaling in Helicobacter pylori infection | 2.1E−02 | – |
| NOD-like receptor signaling pathway | 2.6E−02 | – |
| NF-kappa B signaling pathway | 4.0E−02 | – |
| Herpes simplex infection | 5.2E−05 | – |
| Inflammatory bowel disease (IBD) | 1.4E−02 | – |
| Pertussis | 2.2E−05 | – |
| Leishmaniasis | 3.5E−02 | – |
| Legionellosis | 2.2E−02 | – |
| Tuberculosis | 3.9E−09 | – |
| Amoebiasis | 1.9E−03 | – |
| Platelet activation | – | 1.8E−03 |
| Transcriptional misregulation in cancer | – | 3.5E−04 |
| Inflammatory mediator regulation of TRP channels | – | 1.1E−03 |
| Regulation of lipolysis in adipocytes | – | 1.8E−02 |
| Phosphatidylinositol signaling system | – | 2.3E−04 |
| Tight junction | – | 1.8E−02 |
| Inositol phosphate metabolism | – | 1.5E−02 |
| Axon guidance | – | 7.7E−03 |
| Notch signaling pathway | – | 5.0E−04 |
| PPAR signaling pathway | – | 5.0E−02 |
| Retinol metabolism | – | 2.3E−02 |
| Dilated cardiomyopathy | – | 1.1E−02 |
| Hypertrophic cardiomyopathy (HCM) | – | 7.1E-03 |
| Arrhythmogenic right ventricular cardiomyopathy (ARVC) | – | 3.0E-04 |
FDRs of selected common pathways, unique human pathways, and unique mouse pathways are shown